eye diseases

Pharma

JPM: Novartis CEO refutes respiratory, eye drug sell-off report

Novartis is committed asthma drug Xolair and its eye disease portfolio, including gene therapies, CEO Vas Narasimhan said despite a sell-off rumor.
Angus Liu Jan 9, 2023 4:56pm

Genentech starts phase 2 trial to optimize cell therapy delivery

Nov 28, 2022 10:20am

Apellis' closely watched eye drug gets new FDA goal date

Nov 18, 2022 12:03pm

Roche touts Vabysmo toe-to-toe data against Eylea in RVO

Oct 27, 2022 10:55am

Tarsus launches campaign for misdiagnosed eyelid condition

Sep 30, 2022 11:03am

Eylea set to battle back at Roche's Vabysmo

Sep 7, 2022 6:52pm